An updated review of experimental rodent models of pulmonary hypertension and left heart disease
Left heart disease (LHD) is the leading cause of pulmonary hypertension (PH). Its recent growth has not been matched by the design of therapeutic agents directly targeting the disease. Effective therapies approved for pulmonary arterial hypertension (PAH) have been shown to be inefficient in patient...
Main Author: | Magdalena Jasińska-Stroschein |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1308095/full |
Similar Items
-
Animal models of pulmonary hypertension due to left heart disease
by: Shao‐Fei Liu, et al.
Published: (2022-06-01) -
Searching for Effective Treatments in HFpEF: Implications for Modeling the Disease in Rodents
by: Magdalena Jasińska-Stroschein
Published: (2023-10-01) -
Biomechanical and Mechanobiological Drivers of the Transition From PostCapillary Pulmonary Hypertension to Combined Pre−/PostCapillary Pulmonary Hypertension
by: Betty J. Allen, et al.
Published: (2023-02-01) -
Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease
by: Athanasios Charalampopoulos, et al.
Published: (2018-06-01) -
Management of Pulmonary Hypertension in Patients on Left Ventricular Assist Device Support
by: Mahmoud Salem, et al.
Published: (2022-09-01)